<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5564-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GLUCOPHAGE XR 750MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK HEALTHCARE KGAA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK HEALTHCARE KGAA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SERONO EUROPE LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Glucophage XR prolonged release tablets contain the active ingredient metformin hydrochloride and belong to a group of medicines called biguanides, used in the treatment of Type 2 (non-insulin dependent) diabetes mellitus.<br />Glucophage XR is used together with diet and exercise to lower the risk of developing Type 2 diabetes in overweight adults, when diet and exercise alone for 3 to 6 months have not been enough to control blood glucose (sugar). You are at high risk of developing Type 2 diabetes if you have additional conditions like high blood pressure, age above 40 years, an abnormal amount of lipids (fat) in the blood or a history of diabetes during pregnancy.<br />The medicine is particularly effective if you are aged below 45 years, are very overweight, have high blood glucose levels after a meal or developed diabetes during pregnancy.<br />Glucophage XR is used for the treatment of Type 2 diabetes when diet and exercise changes alone have not been enough to control blood glucose (sugar). Insulin is a hormone that enables body tissues to take glucose from the blood and to use it for energy or for storage for future use. People with Type 2 diabetes do not make enough insulin in their pancreas or their body does not respond properly to the insulin it does make. This causes a buildup of glucose in the blood which can cause a number of serious long-term problems so it is important that you continue to take your medicine, even though you may not have any obvious symptoms. Glucophage XR makes the body more sensitive to insulin and helps return to normal the way your body uses glucose.<br />Glucophage XR is associated with either a stable body weight or modest weight loss.<br />Glucophage XR Prolonged Release Tablets are specially made to release the drug slowly in your body and therefore are different to many other types of tablet containing metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Do not take Glucophage XR if:<br />&bull; you are allergic to metformin or to any of the other ingredients of this medicine (listed in section 6). An allergic reaction may cause a rash, itching or shortness of breath.<br />&bull; you have liver problems<br />&bull; you have severely reduced kidney function<br />&bull; you have uncontrolled diabetes, with, for example, severe hyperglycemia (high blood glucose), nausea, vomiting, diarrhea, rapid weight loss, lactic acidosis (see &#39;Risk of lactic acidosis&#39; below) or ketoacidosis. Ketoacidosis is a condition in which substances called &#39;ketone bodies&#39; accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach<br />pain, fast and deep breathing, sleepiness or your breath developing an unusual, fruity smell.<br />&bull; you have lost too much water from your body (dehydration). Dehydration may lead to kidney problems, which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&#39;).<br />&bull; you have a severe infection, such as an infection affecting your lung or bronchial system or your kidney. Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&#39;).<br />&bull; you have been treated for acute heart problems or have recently had a heart attack or have severe circulatory problems or breathing difficulties. This may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&#39;).<br />&bull; you are a heavy drinker of alcohol.<br />&bull; you are under 18 years of age.<br />Warnings and precautions<br />Risk of lactic acidosis<br />Glucophage XR may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has reduced supply of oxygen (such as acute severe heart disease).<br />If any of the above apply to you, talk to your doctor for further instructions.<br />Stop taking Glucophage XR for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instructions.<br />Stop taking Glucophage XR and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.<br />Symptoms of lactic acidosis include:<br />&bull; vomiting<br />&bull; stomach ache (abdominal pain)<br />&bull; muscle cramps<br />&bull; a general feeling of not being well with severe tiredness<br />&bull; difficulty in breathing<br />&bull; reduced body temperature and heartbeat<br />Lactic acidosis is a medical emergency and must be treated in a hospital.<br />If you need to have major surgery, you must stop taking Glucophage XR during and for some time after the procedure. Your doctor will decide when you must stop and when to restart your treatment with Glucophage XR.<br />During treatment with Glucophage XR, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.</p><p dir="ltr">You may see some remains of the tablets in your stools. Do not worry- this is normal for this type of tablet.<br />You should continue to follow any dietary advice that your doctor has given you and you should make sure that you eat carbohydrates regularly throughout the day.<br />Do not stop taking this medicine without speaking to your doctor.<br />Other medicines and Glucophage XR<br />If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Glucophage XR before or at the time of injection. Your doctor will decide when you must stop and when to restart your treatment with Glucophage XR.<br />Tell your doctor if you are taking, have recently taken or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Glucophage XR. It is especially important to mention the following:<br />&bull; Medicines which increase urine production (diuretics (water tablets) such as furosemide).<br />&bull; Medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib).<br />&bull; Certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists).<br />&bull; Steroids such as prednisolone, mometasone, beclomethasone.<br />&bull; Sympathomimetic medicines including epinephrine and dopamine used to treat heart attacks and low blood pressure. Epinephrine is also included in some dental anesthetics.<br />&bull; Medicines that may change the amount of Glucophage XR in your blood, especially if you have reduced kidney function (such as verapamil, rifampicin, cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, crizotinib, olaparib).<br />Glucophage XR with alcohol<br />Avoid excessive alcohol intake while taking Glucophage XR since this may increase the risk of lactic acidosis (see section &#39;Warnings and precautions&#39;).<br />Pregnancy and breast-feeding<br />Do not take Glucophage XR if you are pregnant or breast feeding. Ask your doctor or pharmacist for advice before taking any medicine.<br />Driving and using machines<br />Glucophage XR taken on its own does not cause &#39;hypos&#39; (symptoms of low blood sugar or hypoglycemia, such as faintness, confusion and increased sweating) and therefore should not affect your ability to drive or use machinery.<br />You should be aware, however, that Glucophage XR taken with other antidiabetic medicines can cause hypos, so in this case you should take extra care when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Your doctor may prescribe Glucophage XR for you to take on its own, or in combination with other oral antidiabetic medicines or insulin.<br />Always take Glucophage XR exactly as your doctor has told you.<br />You should check with your doctor or pharmacist if you are not sure. Swallow the tablets whole with a glass of water, do not chew.<br />Recommended dose<br />Usually you will start treatment with 500 milligrams Glucophage XR daily. After you have been taking Glucophage XR for about 2 weeks, your doctor may measure your blood sugar and adjust the dose.<br />The maximum daily dose is 2000 milligrams of Glucophage XR.<br />If you have reduced kidney function, your doctor may prescribe a lower dose.<br />Normally, you should take the tablets once a day, with your evening meal.<br />In some cases, your doctor may recommend that you take the tablets twice a day. Always take the tablets with food.<br />If you take more Glucophage XR than you should<br />If you take extra tablets by mistake you need not worry, but if you have unusual symptoms, contact your doctor. If the overdose is large, lactic acidosis is more likely. Symptoms of lactic acidosis are non-specific, such as vomiting, bellyache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. Further symptoms are reduced body temperature and<br />heartbeat. If you experience some of these symptoms, you should immediately seek medical attention, as lactic acidosis may lead to coma. Stop taking Glucophage XR immediately and contact a doctor or the nearest hospital straightaway.<br />If you forget to take Glucophage XR<br />Take it as soon as you remember with some food. Do not take a double dose to make up for a forgotten dose.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, Glucophage XR can cause side effects, although not everybody gets them. The following side effects may occur:<br />Glucophage XR may cause a very rare (may affect up to 1 user in 10,000) but very serious side effect called lactic acidosis (see section &#39;Warnings and precautions&#39;). If this happens, you must stop taking Glucophage XR and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.<br />Glucophage XR may cause abnormal liver function tests and hepatitis (inflammation of the liver) which may result in jaundice (may affect up to 1 user in 10,000). If you develop yellowing of the eyes and/or skin contact your doctor immediately.<br />Other possible side effects are listed by frequency as follows:<br />Very common (affects more than 1 person in 10):<br />&bull; Diarrhea, nausea, vomiting, stomach ache or loss of appetite. If you get these, do not stop taking the tablets as these symptoms will normally go away in about 2 weeks. It helps if you take the tablets with or immediately after a meal.<br />Common (affects less than 1 person in 10, but more than 1 person in 100):<br />&bull; Taste disturbance<br />Very rare (affects less than 1 person in 10,000):<br />&bull; Decreased vitamin B12 levels<br />&bull; Skin rashes including redness, itching and hives.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep Glucophage XR tablets out of the sight and reach of children.<br />Do not use them after the expiry date that is printed on the pack after &quot;EXP:&quot;. The expiry date refers to the last day of that month.<br />This medicinal product does not require any special storage conditions.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Each prolonged release tablet contains 500, 750 or 1000 milligrams of the active ingredient metformin hydrochloride. The other ingredients are magnesium stearate, Carmellose sodium and Hypromellose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The 750 milligram tablets are white to off -white and capsule-shaped with '750' on one side and 'MERCK' on the other side.
Glucophage XR is supplied in packs of 30 prolonged release tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder &nbsp;</strong></p><p>&nbsp;</p><p dir="ltr">Merck Serono Ltd,</p><p dir="ltr">5 New Square,</p><p dir="ltr">Bedfont Lakes Business Park,</p><p dir="ltr">Felltham, Middlesex, TW14 8HA</p><p dir="ltr">United Kingdom</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer </strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Merck Healthcare KGaA,</p><p dir="ltr">Frankfurter Str. 250,</p><p dir="ltr">64293 Darmstadt, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>- تحتوي أقراص الإفراج المطول جلوكوفاج اكس ار على المادة الفعالة المیتفورمین ھیدروكلورید وتنتمي إلى مجموعة<br />من الأدویة تسمى بیجوناید ، وتستخدم في علاج داء السكري من النوع 2 (غیر المعتمد على الأنسولین).<br />- یستخدم جلوكوفاج اكس ار مع الحمیة والتمرینات لخفض خطر الإصابة بالنوع الثاني من داء السكري لدى البالغین الذین<br />یعانون من زیادة الوزن ، عندما لا یكون النظام الغذائي والتمرین بمفردھما لمدة 3 إلى 6 أشھر كافیین للسیطرة على<br />نسبة الجلوكوز في الدم (السكر). أنت في خطر كبیر للإصابة بمرض السكري من النوع 2 إذا كنت تعاني من حالات<br />إضافیة مثل ارتفاع ضغط الدم ، أو العمر فوق 40 عامًا ، أو كمیة غیر طبیعیة من الدھون (الدھون) في الدم أو تاریخ<br />مرض السكري أثناء الحمل.<br />- ھذا الدواء فعال بشكل خاص إذا كان عمرك أقل من 45 عامًا ، أو یعاني من زیادة الوزن ، أو ارتفاع مستویات السكر<br />في الدم بعد الوجبة أو الإصابة بمرض السكر أثناء الحمل.<br />- یستخدم جلوكوفاج اكس ار لعلاج داء السكري من النوع 2 عندما لا تكون التغییرات في النظام الغذائي والتمارین بمفرده<br />كافیة للسیطرة على نسبة الجلوكوز في الدم (السكر). الأنسولین ھو ھرمون یمكّن أنسجة الجسم من تناول الجلوكوز من<br />الدم واستخدامھ في الطاقة أو للتخزین للاستخدام في المستقبل. الأشخاص المصابون بداء السكري من النوع 2 لا<br />یصنعون كمیة كافیة من الأنسولین في البنكریاس أو أن الجسم لا یستجیب بشكل صحیح للإنسولین الذي یصنعھ. یؤدي<br />ھذا إلى تراكم نسبة الجلوكوز في الدم مما قد یؤدي إلى عدد من المشاكل الخطیرة طویلة الأجل ، لذلك من المھم أن<br />تستمر في تناول الدواء ، على الرغم من عدم ظھور أعراض واضحة لك .جلوكوفاج اكس ار یجعل الجسم أكثر حساسیة<br />للأنسولین ویساعد على العودة إلى طبیعتھ بالطریقة التي یستخدم بھا الجسم الجلوكوز.<br />- یرتبط جلوكوفاج اكس ار إما بوزن جسم ثابت أو بخسارة وزن متواضعة.<br />- تُصنع أقراص جلوكوفاج اكس ار ذات التحریر المطول من أجل إطلاق الدواء ببطء في جسمك وبالتالي فھي تختلف عن<br />العدید من الأنواع الأخرى من الأقراص التي تحتوي على المیتفورمین.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم جلوكوفاج اكس ار:<br />- لدیك حساسیة من المیتفورمین أو لأي من المكونات الأخرى لھذا الدواء (المذكورة في القسم 6). قد یسبب تفاعل الحساسیة<br />حدوث طفح جلدي أو حكة أو ضیق في التنفس.<br />- لدیك مشاكل في الكبد<br />- قللت بشدة من وظائف الكلى<br />- لدیك مرض السكري غیر المنضبط ، على سبیل المثال ، ارتفاع السكر في الدم الشدید (ارتفاع السكر في الدم) ، والغثیان ،<br />والتقیؤ ، والإسھال ، وفقدان الوزن السریع ، الحماض اللبني (راجع &quot;خطر الحماض اللبني&quot; أدناه) أو الحماض الكیتوني.<br />الحماض الكیتوني ھو حالة تتراكم فیھا المواد المسماة &quot;أجسام الكیتون&quot; في الدم والتي یمكن أن تؤدي إلى غیبوبة السكري.<br />تشمل الأعراض آلام في المعدة ، والتنفس السریع والعمیق ، والنعاس أو أنفاسك التي تنبعث منھا رائحة فاكھیھ غیر عادیة.<br />- فقدت الكثیر من الماء من الجسم (الجفاف). قد یؤدي الجفاف إلى مشاكل في الكلى ، مما قد یعرضك لخطر الإصابة بالحماض<br />اللبني (انظر &quot;التحذیرات والاحتیاطات&quot;).<br />- لدیك عدوى شدیدة ، مثل العدوى التي تصیب الرئة أو الشعب الھوائیة أو كلیتك. قد تؤدي الالتھابات الحادة إلى مشاكل في<br />الكلى ، مما قد یعرضك لخطر الإصابة بالحماض اللبني (انظر &quot;التحذیرات والاحتیاطات&quot;).<br />- عولجت من مشاكل حادة في القلب أو كنت قد تعرضت مؤخر ا لأزمة قلبیة أو لدیك مشاكل في الدورة الدمویة أو صعوبات<br />في التنفس. قد یؤدي ذلك إلى نقص في تزوید الأكسجین بالأنسجة مما قد یعرضك لخطر الإصابة بالحماض اللبني (انظر<br />&quot;التحذیرات والاحتیاطات&quot;).<br />- أنت تشرب الكحولیات بكثرة.<br />- عمرك أقل من 18 عامًا.<br />تحذیرات واحتیاطات<br />- خطر الحماض اللبني<br />جلوكوفاج اكس ار قد یتسبب في حدوث آثار جانبیة نادرة جدًا ولكنھا خطیرة جدًا تسمى الحماض اللبني ، خاصة إذا كانت كلیتیك لا<br />تعملان بشكل صحیح. یزداد خطر الإصابة بحماض اللبنیك أیضًا بسبب مرض السكري غیر المنضبط ، والتھابات خطیرة ، والصیام<br />الطویل أو تناول الكحول ، والجفاف (انظر مزید من المعلومات أدناه) ، ومشاكل في الكبد وأي حالات طبیة یكون فیھا جزء من الجسم<br />یعاني من نقص في إمدادات الأوكسجین ( مثل مرض القلب الحاد الحاد).<br />توقف عن تناول جلوكوفاج اكس ار لفترة قصیرة إذا كان لدیك حالة قد تترافق مع الجفاف (فقدان كبیر لسوائل الجسم) مثل القيء<br />الشدید والإسھال والحمى والتعرض للحرارة أو إذا كنت تشرب كمیات أقل من السوائل عن المعتاد. تحدث إلى طبیبك للحصول على<br />مزید من التعلیمات.<br />توقف عن تناول جلوكوفاج اكس ار واتصل بالطبیب أو أقرب مستشفى على الفور إذا واجھت بعض أعراض الحماض اللبني ، لأن<br />ھذه الحالة قد تؤدي إلى غیبوبة.<br />تشمل أعراض الحماض اللبني:<br />- قيء<br />- آلام في المعدة (آلام في البطن)<br />- تشنجات العضلات<br />- شعور عام بعدم الشعور بالتعب الشدید<br />- صعوبة في التنفس<br />- انخفاض درجة حرارة الجسم ونبضات القلب<br />الحماض اللبني ھو حالة طبیة طارئة ویجب علاجھا في المستشفى.<br />إذا كنت بحاجة إلى إجراء عملیة جراحیة كبیرة ، فیجب علیك التوقف عن تناول جلوكوفاج اكس ار أثناء العملیة وبعدھا لبعض الوقت,<br />سیقرر طبیبك متى یجب أن تتوقف ومتى ستستأنف علاجك باستخدام جلوكوفاج اكس ار.<br />أثناء العلاج مع جلوكوفاج اكس ار ، سیقوم طبیبك بفحص وظائف الكلى الخاصة بك على الأقل مرة واحدة في السنة أو أكثر إذا كنت<br />من كبار السن و / أو إذا كنت تعاني من تدھور وظائف الكلى.</p><p>&nbsp;</p><p>إذا كان عمرك أكبر من 75 عامًا ، فیجب ألا تبدأ المعالجة ب جلوكوفاج اكس ار لتقلیل خطر الإصابة بالنوع الثاني من مرض<br />السكري.<br />قد ترى بعض بقایا الأقراص في برازك. لا تقلق - ھذا طبیعي لھذا النوع من الاقراص.<br />یجب أن تستمر في متابعة أي نصیحة غذائیة قدمھا لك طبیبك وعلیك التأكد من تناول الكربوھیدرات بانتظام طوال الیوم. لا تتوقف عن<br />تناول ھذا الدواء دون التحدث إلى طبیبك.<br />الأدویة الأخرى جلوكوفاج اكس ار.<br />إذا كنت بحاجة إلى حقن وسیط تباین یحتوي على الیود في مجرى الدم لدیك ، في سیاق الأشعة السینیة أو المسح الضوئي ، یجب علیك<br />التوقف عن تناول جلوكوفاج اكس ار قبل أو في وقت الحقن. سیقرر طبیبك متى یجب أن تتوقف ومتى ستستأنف علاجك باستخدام<br />جلوكوفاج اكس ار.<br />أخبر طبیبك إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدویة أخرى. قد تحتاج إلى اختبارات وظائف الجلوكوز والكلى في الدم<br />بشكل متكرر ، أو قد یحتاج طبیبك إلى ضبط جرعة جلوكوفاج اكس ار. من المھم بشكل خاص ذكر ما یلي:<br />- الأدویة التي تزید من إنتاج البول (مدرات البول (أقراص الماء) مثل فوروسیمید).<br />مثل الإیبوبروفین والسیلیكوكسیب) ، COX- و 2 NSAID - الأدویة المستخدمة لعلاج الألم والالتھابات (مثبطات<br />(II ومضادات مستقبلات الأنجیوتنسین ACE - عض الأدویة لعلاج ارتفاع ضغط الدم (مثبطات<br />- المنشطات مثل بریدنیزولون ، مومیتازون ، بیكلومیثاسون.<br />- الأدویة المقلدة بما في ذلك الإیبینیفرین والدوبامین المستخدم لعلاج النوبات القلبیة وانخفاض ضغط الدم. أدرینالین مدرج<br />أیضًا في بعض التخدیر السني.<br />- أدویة التي قد تغیر كمیة جلوكوفاج اكس ار في دمك ، خاصة إذا كنت قد قللت من وظائف الكلى (مثل فیرابامیل ،<br />ریفامبیسین ، السیمیتیدین ، دولوتیجرافیر ، رانولازین ، تریمیثوبریم ، فاندیتانیب ، إیزافوكونازول ، كریزوتینیب ،<br />أولاباریب).<br />جلوكوفاج اكس ار مع الكحول:<br />تجنب الإفراط في تناول الكحول أثناء تناول جلوكوفاج اكس ار لأن ذلك قد یزید من خطر الإصابة بالحماض اللبني (انظر القسم<br />&quot;التحذیرات والاحتیاطات&quot;).<br />الحمل والإرضاع<br />لا تأخذ جلوكوفاج اكس ار إذا كنت حاملا أو مرضعة, اسأل طبیبك أو الصیدلي للحصول على المشورة قبل تناول أي دواء.<br />القیادة واستعمال الآلات<br />جلوكوفاج اكس ار الذي یتم تناولھ بمفرده لا یسبب &quot;انخفاض في سكر الدم&quot; (أعراض انخفاض السكر في الدم أو نقص السكر في الدم<br />، مثل الإغماء والارتباك وزیادة التعرق) وبالتالي یجب ألا تؤثر على قدرتك على القیادة أو استخدام الآلات.<br />ومع ذلك ، یجب أن تدرك أن جلوكوفاج اكس ار التي یتم تناولھا مع أدویة أخرى مضادة لمرض السكر یمكن أن تسبب انخفاضًا في<br />معدل السكر ، لذا في ھذه الحالة یجب أن تتوخى الحذر عند القیادة أو تشغیل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قد یصف لك الطبیب جلوكوفاج اكس ار لتتناولھ بنفسك ، أو بالاشتراك مع الأدویة الأخرى المضادة لمرض السكر أو الأنسولین.<br />دائما استخدم جلوكوفاج اكس ار تماما كما أخبرك طبیبك.<br />یجب علیك استشارة طبیبك أو الصیدلي إذا كنت غیر متأكد. ابتلاع الأقراص بالكامل مع كوب من الماء ، لا تمضغھ.<br />الجرعة<br />عادة سوف تبدأ العلاج مع 750 مللیغرام جلوكوفاج اكس ار یومیا. بعد تناول جلوكوفاج اكس ار لمدة أسبوعین تقریباً ، یمكن<br />لطبیبك قیاس نسبة السكر في الدم وضبط الجرعة. الجرعة الیومیة القصوى ھي 2000 مللیغرام من جلوكوفاج اكس ار, إذا قمت<br />بتخفیض وظائف الكلى ، فقد یصف لك الطبیب جرعة أقل عادة ، یجب أن تأخذ الاقراص مرة واحدة في الیوم ، مع وجبة المساء.<br />في بعض الحالات ، قد یوصي طبیبك بتناول الأقراص مرتین في الیوم. دائما تناول ألاقراص مع الطعام.</p><p>اذا تناولت اقراص جلوكوفاج اكس ار أكثر مما یجب<br />اذا تناولت أقراص إضافیة عن طریق الخطأ ، فلا داعي للقلق ، ولكن إذا كان لدیك أعراض غیر عادیة ، فاتصل بطبیبك. إذا كانت<br />الجرعة الزائدة كبیرة ، فإن الحماض اللبني أكثر احتمالاً. أعراض الحماض اللبني غیر محددة ، مثل القيء ، وجع البطن ، وتشنجات<br />العضلات ، والشعور العام بعدم التحسن مع التعب الشدید ، وصعوبة التنفس. یتم تقلیل الأعراض الأخرى درجة حرارة الجسم<br />ونبضات القلب. إذا واجھت بعضًا من ھذه الأعراض ، یجب علیك التماس العنایة الطبیة على الفور ، لأن الحماض اللبني قد یؤدي<br />إلى غیبوبة. توقف عن تناول جلوكوفاج اكس ار على الفور واتصل بالطبیب أو أقرب مستشفى على الفور.<br />إذا نسیت استعمال جلوكوفاج اكس ار<br />خذھا بمجرد تذكرھا مع بعض الطعام. لا تأخذ جرعة مضاعفة لتعویض جرعة منسیة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جمیع الأدویة ، یمكن أن یسبب جلوكوفاج اكس ار آثارًا جانبیة ، على الرغم من أن الجمیع لا یصاب بھا. قد تحدث الآثار الجانبیة<br />التالیة:<br />جلوكوفاج اكس ار قد یتسبب في حدوث اثار جانبیھ نادره للغایة (قد یؤثر على ما یصل إلى مستخدم واحد في 10000 ) ولكن لھ آثار<br />جانبیة خطیرة للغایة تسمى الحماض اللبني (انظر القسم &quot;التحذیرات والاحتیاطات&quot;). إذا حدث ھذا ، فیجب علیك التوقف عن تناول<br />جلوكوفاج اكس ار والاتصال بالطبیب أو أقرب مستشفى على الفور ، لأن الحماض اللبني قد یؤدي إلى غیبوبة.<br />جلوكوفاج اكس ار قد یسبب اختبارات وظائف الكبد غیر الطبیعیة والتھاب الكبد (التھاب الكبد) الذي قد یؤدي إلى الیرقان (قد یؤثر<br />على ما یصل إلى مستخدم واحد في 10000 ). إذا كنت تعاني من اصفرار العینین و / أو الجلد ، فاتصل بطبیبك على الفور.<br />تصُنف الآثار الجانبیة استنادًا إلى معدل حدوثھا إلى الفئات التالیة:<br />&bull; الشائعة: قد تصیب 1 من كل 10 أشخاص<br />&bull; غیر الشائعة: قد تصیب 1 من كل 100 شخص<br />&bull; النادرة: قد تصیب حتى 1 من بین كل 1,000 شخص<br />&bull; النادرة جدا:ً قد تصیب حتى 1 من بین كل 10,000 شخص<br />&bull; غیر المعروفة: یتعذرّ تقدیر معدل حدوثھا من البیانات المتوفرة.<br />الآثار الجانبیة الشائعة جدا (قد تصیب أكثر من 1 من كل 10 أشخاص):<br />&bull; الإسھال والغثیان والقيء وآلام المعدة أو فقدان الشھیة. إذا أصبت بھذه ، لا تتوقف عن تناول الأقراص لأن ھذه الأعراض<br />ستزول عادة خلال أسبوعین تقریباً. یساعد إذا تناولت أقراص مع أو بعد وجبة مباشرة.<br />( الآثار الجانبیة الشائعة( یؤثر على أقل من شخص واحد في 10 ، ولكن أكثر من شخص واحد في 100<br />&bull; اضطراب المذاق.<br />:( الآثار الجانبیة النادرة جدًا (یصیب أقل من شخص واحد لكل 10000<br />&bull; انخفاض مستویات فیتامین ب 12<br />&bull; طفح جلدي بما في ذلك الاحمرار والحكة وخلایا النحل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>حافظ على أقراص جلوكوفاج اكس ار بعیدة عن مرأى ومدى وصول الأطفال.<br />یشیر تاریخ انتھاء الصلاحیة إلى الیوم &quot;EXP:&quot;. - لا تستخدمھا بعد تاریخ انتھاء الصلاحیة المطبوع على العبوة بعد<br />الأخیر من ذلك الشھر.<br />- احفظھ في درجة حراره اقل من 25 درجھ مئویھ.<br />- لا یتطلب ھذا المنتج الطبي أي شروط تخزین خاصة.<br />- لا ینبغي التخلص من الأدویة عن طریق المیاه العادمة أو النفایات المنزلیة. اسأل الصیدلي عن كیفیة التخلص من الأدویة<br />التي لم تعد مطلوبة. ومن شأن ھذه التدابیر أن تساعد على حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ. ماذا تحتوي علیھ ألاقراص<br />یحتوي كل قرص ذات تحریر مطول على 750 مللیغرام من المادة الفعالة میتفورمین ھیدروكلورید. المكونات الأخرى ھي ستیرات<br />المغنیسیوم وصودیوم كارمیلوز وھیبومیلوز</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تحتوي أقراص 750 مللیغرام على لون أبیض إلى خارج الأبیض وعلى شكل كبسولة مع &quot; 750 &quot; من جانب و الجانب الآخر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p>&nbsp;</p><p dir="RTL">ميرك سيرونو المحدودة،</p><p dir="RTL">5 ساحة جديدة,</p><p dir="RTL">حديقة بيدفونت للبحيرات التجارية,</p><p dir="RTL">فيثام، ميدلسبره، TW14 8HA</p><p dir="RTL">المملكة المتحدة</p><p>&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p>&nbsp;</p><p>میرك هيلث كير كي جي اي</p><p>فرانكفورتر شتراسھ 250</p><p>&nbsp;64293 دارمشتات</p><p>ألمانیا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابريل 2021 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Glucophage XR 750 mg prolonged release tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                750 mg: One prolonged release tablet contains 750 mg metformin hydrochloride corresponding to 585 mg metformin base.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged release tablet.
750 mg: White capsule-shaped, biconvex tablet, debossed on one side with '750' and on the other side with 'Merck'.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull; Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are:<br />- at high risk for developing overt type 2 diabetes mellitus (see section 5.1) and<br />- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months<br />Treatment with Glucophage XR must be based on a risk score incorporating appropriate measures of glycemic control and including evidence of high cardiovascular risk (see section 5.1).<br />Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.<br />*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose<br />&bull; Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control. Glucophage XR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults with normal renal function (GFR &ge; 90 mL/min)<br />Reduction in the risk or delay of the onset of type 2 diabetes<br />&bull; Metformin should only be considered where intensive lifestyle modifications for 3 to 6 months have not resulted in adequate glycemic control.<br />&bull; The therapy should be initiated with one tablet Glucophage XR 500 mg once daily with the evening meal.<br />&bull; After 10 to 15 days dose adjustment on the basis of blood glucose measurements is recommended (OGTT and/or FPG and/or HbA1C values to be within the normal range). A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 4 tablets (2000 mg) once daily with the evening meal.<br />&bull; It is recommended to regularly monitor (every 3-6 months) the glycemic status (OGTT and/or FPG and/or HbA1c value) as well as the risk factors to evaluate whether treatment needs to be continued, modified or discontinued.<br />&bull; A decision to re-evaluate therapy is also required if the patient subsequently implements improvements to diet and/or exercise, or if changes to the medical condition will allow increased lifestyle interventions to be possible.<br />Monotherapy in Type 2 diabetes mellitus and combination with other oral antidiabetic agents:<br />&bull; The usual starting dose is one tablet of Glucophage XR 500 mg once daily.</p><p>&nbsp;</p><p>&bull; After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 4 tablets daily.<br />&bull; Dosage increases should be made in increments of 500 mg every 10-15 days, up to a maximum of 2000mg once daily with the evening meal. If glycemic control is not achieved on Glucophage XR 2000mg once daily, Glucophage XR 1000 mg twice daily should be considered, with both doses being given with food. If glycemic control is still not achieved, patients may be switched to standard metformin tablets to a maximum dose of 3000 mg daily.<br />&bull; In patients already treated with metformin tablets, the starting dose of Glucophage XR should be equivalent to the daily dose of metformin immediate release tablets. In patients treated with metformin at a dose above 2000 mg daily, switching to Glucophage XR is not recommended.<br />&bull; If transfer from another oral antidiabetic agent is intended: discontinue the other agent and initiate Glucophage XR at the dose indicated above.<br />&bull; Glucophage XR 750 mg and Glucophage XR 1000 mg are intended for patients who are already treated with metformin tablets (prolonged or immediate release).<br />&bull; The dose of Glucophage XR 750 mg or Glucophage XR 1000 mg should be equivalent to the daily dose of metformin tablets (prolonged or immediate release), up to a maximum dose of 1500 mg or 2000 mg respectively, given with the evening meal.<br />Combination with insulin<br />Metformin and insulin may be used in combination therapy to achieve better blood glucose control. The usual starting dose of Glucophage XR is one 500 mg tablet once daily, while insulin dosage is adjusted on the basis of blood glucose measurements.<br />For patients already treated with metformin and insulin in combination therapy, the dose of Glucophage XR 750 mg or Glucophage XR 1000 mg should be equivalent to the daily dose of metformin tablets up to a maximum of 1500 mg or 2000 mg respectively, given with the evening meal, while insulin dosage is adjusted on the basis of blood glucose measurements. Elderly<br />Due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary (see section 4.4).<br />Benefit in the reduction of risk or delay of the onset of type 2 diabetes mellitus has not been established in patients 75 years and older (see section 5.1) and metformin initiation is therefore not recommended in these patients (see section 4.4).<br />Renal impairment<br />A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.</p><p>&nbsp;</p><p>GFR (mL/min)<br />Total maximum daily dose<br />Additional considerations<br />60-89<br />2000 mg<br />Dose reduction may be considered in relation to declining renal function.<br />45-59<br />2000 mg<br />Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin.<br />The starting dose is at most half of the maximum dose.<br />30-44<br />1000 mg<br />&lt;30<br />-<br />Metformin is contraindicated.<br />Pediatric population<br />In the absence of available data, Glucophage XR should not be used in children.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to metformin or to any of the excipients listed in section 6.1.
• Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
• Diabetic pre-coma
• Severe renal failure (GFR < 30 mL/min).
• Acute conditions with the potential to alter renal function such as:
- dehydration,
- severe infection, - shock
• Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: - decompensated heart failure,
- respiratory failure,
- recent myocardial infarction,
- shock
• Hepatic insufficiency, acute alcohol intoxication, alcoholism
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactic acidosis:<br />Lactic acidosis, a very rare, but serious, metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.<br />In case of dehydration (severe diarrhea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.<br />Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).<br />Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterized by acidotic dyspnea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt; 7.35), increased plasma lactate levels (&gt;5 mmol/L) and an increased anion gap and lactate/pyruvate ratio.<br />Renal function:<br />GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2. Metformin is contraindicated in patients with GFR&lt;30 mL/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3.<br />Cardiac function<br />Patients with heart failure are more at risk of hypoxia and renal insufficiency. In patients with stable chronic heart failure, metformin may be used with a regular monitoring of cardiac and renal function.<br />For patients with acute and unstable heart failure, metformin is contraindicated (see section 4.3).<br />Elderly:<br />Due to the limited therapeutic efficacy data in the reduction of risk or delay of type 2 diabetes in patients 75 years and older, metformin initiation is not recommended in these patients.</p><p>Administration of iodinated contrast agents:<br />Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5.<br />Surgery:<br />Metformin must be discontinued at the time of surgery under general, spinal or epidural anesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.<br />Other precautions:<br />All patients should continue their diet with a regular distribution of carbohydrate intake during the day.<br />Overweight patients should continue their energy-restricted diet.<br />The usual laboratory tests for diabetes monitoring should be performed regularly.<br />Metformin alone never causes hypoglycemia, although caution is advised when it is used in combination with insulin or other oral antidiabetics (e.g. Sulphonylureas or meglitinides).<br />The tablet shells may be present in the faeces. Patients should be advised that this is normal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use not recommended<br />Alcohol<br />Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in case of fasting, malnutrition or hepatic impairment. Iodinated contrast agents<br />Metformin must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4.<br />Combinations requiring precautions for use<br />Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.<br />Medicinal products with intrinsic hyperglycemic activity (e.g. glucocorticoids (systemic and local routes) and sympathomimetics).<br />More frequent blood glucose monitoring may be required, especially at the beginning of treatment. If necessary, adjust the metformin dosage during therapy with the other drug and upon its discontinuation.<br />Organic cation transporters (OCT)<br />Metformin is a substrate of both transporters OCT1 and OCT2.<br />Co-administration of metformin with<br />&bull; Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.<br />&bull; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.<br />&bull; Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.<br />&bull; Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.</p><p>&nbsp;</p><p>Caution is therefore advised, especially in patients with renal impairment, when these drugs are co-administered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Uncontrolled diabetes during pregnancy (gestational or permanent) is associated with increased risk of congenital abnormalities and perinatal mortality.<br />A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital abnormalities. Animal studies do not indicate harmful effects with respect to pregnancy, embryonic or fetal development, parturition or postnatal development (see section 5.3).<br />When the patient plans to become pregnant and during pregnancy, it is recommended that impaired glycemic control or diabetes are not treated with metformin. For diabetes it is recommended that insulin should be used to maintain blood glucose levels as close to normal as possible to reduce the risk of malformations of the fetus.<br />Breast-feeding<br />Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants. However, as only limited data are available, breastfeeding is not recommended during metformin treatment. A decision on whether to discontinue breast-feeding should be made, taking into account the benefit of breastfeeding and the potential risk to adverse effect on the child.<br />Fertility<br />Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metformin monotherapy does not cause hypoglycemia and therefore has no effect on the ability to drive or to use machines.<br />However, patients should be alerted to the risk of hypoglycemia when metformin is used in combination with other antidiabetic agents (e.g. Sulphonylureas, insulin, or meglitinides).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In post marketing data and in controlled clinical studies, adverse event reporting in patients treated with Glucophage XR was similar in nature and severity to that reported in patients treated with Glucophage immediate release.<br />During treatment initiation, the most common adverse reactions are nausea, vomiting, diarrhea, abdominal pain and loss of appetite, which resolve spontaneously in most cases. The following adverse reactions may occur with Glucophage XR.<br />Frequencies are defined as follows: very common: &gt;1/10; common &ge;1/100, &lt;1/10; uncommon &ge;1/1,000, &lt;1/100; rare &ge;1/10,000, &lt;1/1,000; very rare &lt;1/10,000.<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>Metabolism and nutrition disorders<br />Very rare:<br />&bull; Lactic acidosis (see 4.4. Special warnings and precautions for use).<br />&bull; Decrease of vitamin B12 absorption with decrease of serum levels during long-term use of metformin. Consideration of such an aetiology is recommended if a patient presents with megaloblastic anemia.<br />Nervous system disorders<br />Common:<br />&bull; Taste disturbance<br />Gastrointestinal disorders<br />Very common:<br />&bull; Gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. A slow increase of the dose may also improve gastrointestinal tolerability.<br />Hepatobiliary disorders<br />Very rare<br />&bull; Isolated reports of liver function tests abnormalities or hepatitis resolving upon metformin discontinuation.<br />Skin and subcutaneous tissue disorders<br />Very rare:<br />&bull; Skin reactions such as erythema, pruritus, urticaria</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypoglycemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose or concomitant risks of metformin may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and metformin is hemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ORAL ANTI-DIABETICS<br />(A10BA02: Gastrointestinal tract and metabolism)<br />Metformin is a biguanide with antihyperglycemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycemia.<br />Mechanism of action<br />Metformin may act via 3 mechanisms:<br />&bull; reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis.<br />&bull; in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilization<br />&bull; delay of intestinal glucose absorption.<br />Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.<br />Metformin increases the transport capacity of all types of membrane glucose transporters (GLUT).<br />Pharmacodynamic effects<br />In clinical studies, the major non glycemic effect of metformin is either weight stability or modest weight loss. In humans, independently of its action on glycaemia, immediate release metformin has favorable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: immediate release metformin reduces total cholesterol, LDL cholesterol and triglyceride levels. A similar action has not been demonstrated with the prolonged release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.<br />Clinical efficacy:<br />Reduction in the risk or delay of type 2 diabetes mellitus<br />The Diabetes Prevention Program (DPP) was a multicenter randomized controlled clinical trial in adults assessing the efficacy of an intensive lifestyle intervention or metformin to prevent or delay the development of type 2 diabetes mellitus. Inclusion criteria were age &ge;25 years, BMI &ge;24 kg/m2 (&ge;22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 95 &ndash; 125 mg/dl (or &le;125 mg/dl for American Indians). Patients were either treated with intensive lifestyle intervention, 2x850 mg metformin plus standard lifestyle change, or placebo plus standard lifestyle change.<br />The mean baseline values of the DPP participants (n=3,234 for 2.8 years) were age 50.6&plusmn;10.7 years, 106.5&plusmn;8.3 mg/dl fasted plasma glucose, 164.6&plusmn;17.0 mg/dl plasma glucose two hours after an oral glucose load, and 34.0&plusmn;6.7 kg/m2 BMI. Intensive lifestyle intervention as well as metformin significantly reduced the risk of developing overt diabetes compared to placebo, 58% (95% CI 48-66%) and 31% (95% CI 17-43%), respectively.<br />The advantage of the lifestyle intervention over metformin was greater in older persons.<br />The patients who benefited most from the metformin treatment were aged below 45 years, with a BMI equal or above 35kg/m2, a baseline glucose 2 h value of 9.6-11.0 mmol/l, a baseline HbA1C equal or above 6.0% or with a history of gestational diabetes.</p><p>To prevent one case of overt diabetes during the three years in the whole population of the DPP, 6.9 patients had to participate in the intensive lifestyle group and 13.9 in the metformin group. The point of reaching a cumulative incidence of diabetes equal to 50% was delayed by about three years in the metformin group compared to placebo. The Diabetes Prevention Program Outcomes Study (DPPOS) is the long-term follow-up study of the DPP including more than 87% of the original DPP population for long-term follow up.<br />Among the DPPOS participants (n=2776), the cumulative incidence of diabetes at year 15 is 62% in the placebo group, 56% in the metformin group, and 55% in the intensive lifestyle intervention group. Crude rates of diabetes are 7.0, 5.7 and 5.2 cases per 100 person‐years among the placebo, metformin, and intensive lifestyle participants, respectively. Reductions in the diabetes risk were of 18% (hazard ratio (HR) 0.82, 95% CI 0.72&ndash;0.93; p=0.001) for the metformin group and 27% (HR 0.73, 95% CI 0.65&ndash;0.83; p&lt;0.0001) for the intensive lifestyle intervention group, when compared with the placebo group. For an aggregate microvascular endpoint of nephropathy, retinopathy and neuropathy, the outcome was not significantly different between the treatment groups, but among the participants who had not developed diabetes during DPP/DPPOS, the prevalence of the aggregate microvascular outcome was 28% lower compared with those who had developed diabetes (Risk Ratio 0.72, 95% CI 0.63&ndash;0.83; p&lt;0.0001). No prospective comparative data for metformin on macrovascular outcomes in patients with IGT and/or IFG and/or increased HbA1C is available.<br />Published risk factors for type 2 diabetes include: Asian or black ethnic background, age above 40, dyslipidemia, hypertension, obesity or being overweight, age, 1st degree family history of diabetes, history of gestational diabetes mellitus, and polycystic ovary syndrome (PCOS).<br />Consideration must be given to current national guidance on the definition of prediabetes. Patients at high risk should be identified by a validated risk-assessment tool.<br />Treatment of type 2 diabetes mellitus<br />The prospective randomized (UKPDS) study has established the long-term benefit of intensive blood glucose control in overweight type 2 diabetic patients treated with immediate release metformin as first-line therapy after diet failure. Analysis of the results for overweight patients treated with metformin after failure of diet alone showed:<br />&bull; a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/ 1000 patient-years) versus diet alone (43.3 events/ 1000 patient-years), p=0.0023, and versus the combined Sulphonylureas and insulin monotherapy groups (40.1 events/ 1000 patient-years), p=0.0034.<br />&bull; a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1000 patient-years, diet alone 12.7 events/ 1000 patient-years, p=0.017;<br />&bull; a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/ 1000 patient- years versus diet alone 20.6 events/ 1000 patient-years (p=0.011), and versus the combined Sulphonylureas and insulin monotherapy groups 18.9 events/ 1000 patient-years (p=0.021);<br />&bull; a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/ 1000 patient-years, diet alone 18 events/ 1000 patient-years (p=0.01)<br />For metformin used as second-line therapy, in combination with a Sulphonylureas, benefit regarding clinical outcome has not been shown.<br />In type 1 diabetes, the combination of metformin and insulin has been used in selected patients, but the clinical benefit of this combination has not been formally established</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />After an oral dose of the prolonged release tablet, metformin absorption is significantly delayed compared to the immediate release tablet with a Tmax at 7 hours (Tmax for the immediate release tablet is 2.5 hours).<br />At steady state, similar to the immediate release formulation, Cmax and AUC are not proportionally increased to the administered dose. The AUC after a single oral administration of 2000mg of metformin prolonged release tablets is similar to that&nbsp;observed after administration of 1000mg of metformin immediate release tablets b.i.d. Intrasubject variability of Cmax and AUC of metformin prolonged release is comparable to that observed with metformin immediate release tablets.<br />When the prolonged release tablet is administered in fasting conditions the AUC is decreased by 30% (both Cmax and Tmax are unaffected).<br />Mean metformin absorption from the prolonged release formulation is almost not altered by meal composition. No accumulation is observed after repeated administration of up to 2000mg of metformin as prolonged release tablets.<br />Following a single oral administration of 1500 mg of Glucophage XR 750 mg, a mean peak plasma concentration of 1193 ng/ml is achieved with a median value of 5 hours and a range of 4 to 12 hours.<br />Glucophage XR 750 mg was shown to be bioequivalent to Glucophage XR 500 mg at a 1500 mg dose with respect to Cmax and AUC in healthy fed and fasted subjects.<br />Following a single oral administration in the fed state of one tablet of Glucophage XR 1000 mg, a mean peak plasma concentration of 1214 ng/ml is achieved with a median time of 5 hours (range of 4 to 10 hours). Glucophage XR 1000 mg was shown to be bioequivalent to Glucophage XR 500 mg at a 1000 mg dose with respect to Cmax and AUC in healthy fed and fasted subjects.<br />When the 1000 mg prolonged release tablet is administered in fed conditions the AUC is increased by 77% (Cmax is increased by 26% and Tmax is slightly prolonged by about 1 hour).<br />Distribution<br />Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean Vd ranged between 63-276 L.<br />Metabolism<br />Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.<br />Elimination<br />Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.<br />When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.<br />Characteristics in specific groups of patients<br />Renal impairment<br />The available data in subjects with moderate renal insufficiency are scarce and no reliable estimation of the systemic exposure to metformin in this subgroup as compared to subjects with normal renal function could be made. Therefore, the dose adaptation should be made upon clinical efficacy/tolerability considerations (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies on safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Magnesium stearate 5.3 mg<br />sodium carboxymethylcellulose 37.5 mg<br />Hypromellose 294.240 mg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store Below 25 &ordm;C This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>750 mg: 14, 20, 28, 30, 50, 56, 60, 84, 90, 100, 112, 120, 180 or 600 tablets in blister strips composed of aluminum foil + PVC or PVC/PVDC (60 g/m&sup2; or 90g/m&sup2;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Merck Serono Ltd, 
5 New Square, 
Bedfont Lakes Business Park, 
Felltham, Middlesex, TW14 8HA 
United Kingdom 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>